Molecular advances have led to a more accurate classification of HGG in CNS5 World Health Organization (WHO) 2021 [1,2]: for glioblastoma (GB) diagnosis, a characteristic histological appearance (poorly differentiated astrocytes, with nuclear atypia, prominent microvascular proliferation, and/or necrosis) combined with an isocitrate dehydrogenase (IDH) wildtype genotype is sufficient. This evidence concerns the gene IDH1 and glioblastoma.